Glenmark arm discovers molecule to treat blood cancer

PTI New Delhi | Updated on March 31, 2011

Glenmark Pharmaceuticals today said it has discovered a new drug molecule which can treat blood and lymph cancer, besides inflammatory disorders.

The novel biological entity, (NBE) ‘GBR 401’, was discovered by the company’s Switzerland-based arm Glenmark Pharmaceuticals SA, the company said in a statement.

“Glenmark will file for phase-I trials in the fourth quarter of FY2011-12,” it added.

The disease areas primarily targeted by GBR 401 are lymphoma and leukaemia of B-cell origin. Leukaemia is a type of cancer of the blood or bone marrow and lymphoma is a form of cancer in the lymphatic cells of the immune system.

GBR 401 also holds the potential to treat inflammatory disorders such as rheumatoid arthritis, it added.

“GBR 401 has been developed using a technologically advanced platform that greatly enhances the efficacy of of the antibody,” said Glenmark Pharmaceuticals SA President, Biologics, Mr Michael Buschle.

Shares of Glenmark Pharmaceuticals were quoting at Rs 284.35 apiece on the Bombay Stock Exchange today, up 0.99 per cent from their previous close.

Published on March 31, 2011

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like